Apatinib, a competitive inhibitor of VEGFR2, has been found to promote ferroptosis by targeting ELOVL6/ACSL4 signaling, supporting the clinical application of apatinib in CRC via a new mechanism [72]. Here, ACSL4 is linked to colorectal carcinoma.